Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance and cross-resistance profile of the diaryltriazine NNRTI and candidate microbicide UAMC01398.

The Journal of antimicrobial chemotherapy - 1 May 2016

Ariën Kevin K, Venkatraj Muthusamy, Michiels Johan, Joossens Jurgen, Vereecken Katleen, Van der Veken Pieter, Heeres Jan, De Winter Hans, Heyndrickx Leo, Augustyns Koen, Vanham Guido

Abstract excerpt

OBJECTIVES: The resistance development, cross-resistance to other NNRTIs and the impact of resistance on viral replicative fitness were studied for the new and potent NNRTI UAMC01398. METHODS: Resistance was selected by dose escalation and by single high-dose selection against a comprehensive panel of NNRTIs used as therapeutics and NNRTIs under investigation for pre-exposure prophylaxis of sexual HIV...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Reverse Transcriptase

Share to Mutation

Share to Virus Replication

Source

Identifiers

PMID: 26850721
DOI: 10.1093/jac/dkv501

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance and cross-resistance profile of the diaryltriazine NNRTI and candidate microbicide UAMC01398.PMID 26850721Read ↗

The Emerging Profile of Cross-Resistance among the Nonnucleoside HIV-1 Reverse Transcriptase InhibitorsSemantic proximity Read ↗

Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.Semantic proximity Read ↗

Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1Semantic proximity Read ↗

Development of enhanced HIV-1 non-nucleoside reverse transcriptase inhibitors with improved resistance and pharmacokinetic profiles.Semantic proximity Read ↗

In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine.Semantic proximity Read ↗

From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infectionSemantic proximity Read ↗

Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development.Semantic proximity Read ↗

An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance.Semantic proximity Read ↗

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1Semantic proximity Read ↗

[Resistance profile of rilpivirine].Semantic proximity Read ↗

In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.Semantic proximity Read ↗

In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.